
    
      The protocol underwent 3 amendments, the last of which (02APR2009) changed the study design
      from a randomized to a non-randomized and non-comparative clinical trial. All of the subjects
      were enrolled under the randomized design with the exception of the last subject. This study
      is not applicable per FDAA Title VIII, Section 801 due to the final trial design. However,
      results are submitted to clinicaltrials.gov due to the majority of study data being collected
      under a randomized (FDAA Title VIII, Section 801 applicable) trial design
    
  